198 related articles for article (PubMed ID: 30442827)
1. Longitudinal Assessment of Patient-reported Outcome Measures in Systemic Sclerosis Patients with Gastroesophageal Reflux Disease - Scleroderma Clinical Trials Consortium.
McMahan ZH; Frech T; Berrocal V; Lim D; Bruni C; Matucci-Cerinic M; Smith V; Melsens K; Proudman S; Zhang J; Mendoza F; Woods M; Khanna D
J Rheumatol; 2019 Jan; 46(1):78-84. PubMed ID: 30442827
[TBL] [Abstract][Full Text] [Related]
2. Responsiveness of the University of California Los Angeles Scleroderma Clinical Trial Consortium gastrointestinal tract 2.0 (UCLA-SCTC-GIT 2.0)to change in scleroderma patients.
Suliman YA; Kafaja S; Alemam M; Shaweesh Y; Tavakoli K; Furst DE
J Scleroderma Relat Disord; 2021 Oct; 6(3):236-241. PubMed ID: 35387210
[TBL] [Abstract][Full Text] [Related]
3. UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract (GIT) 2.0 Reflux Scale Correlates With Impaired Esophageal Scintigraphy Findings in Systemic Sclerosis.
Abignano G; Mennillo GA; Lettieri G; Karadag DT; Carriero A; Padula AA; Del Galdo F; Khanna D; D'Angelo S
J Rheumatol; 2021 Sep; 48(9):1422-1426. PubMed ID: 33452163
[TBL] [Abstract][Full Text] [Related]
4. Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis.
Bodukam V; Hays RD; Maranian P; Furst DE; Seibold JR; Impens A; Mayes MD; Clements PJ; Khanna D
Rheumatology (Oxford); 2011 Feb; 50(2):330-4. PubMed ID: 20884655
[TBL] [Abstract][Full Text] [Related]
5. High-resolution manometry compared with the University of California, Los Angeles Scleroderma Clinical Trials Consortium GIT 2.0 in Systemic Sclerosis.
Abozaid HSM; Imam HMK; Abdelaziz MM; El-Hammady DH; Fathi NA; Furst DE
Semin Arthritis Rheum; 2017 Dec; 47(3):403-408. PubMed ID: 28624173
[TBL] [Abstract][Full Text] [Related]
6. Construct validity of the Patient-Reported Outcomes Measurement Information System gastrointestinal symptom scales in systemic sclerosis.
Nagaraja V; Hays RD; Khanna PP; Spiegel BM; Chang L; Melmed GY; Bolus R; Khanna D
Arthritis Care Res (Hoboken); 2014 Nov; 66(11):1725-30. PubMed ID: 24692332
[TBL] [Abstract][Full Text] [Related]
7. Reliability, validity, and sensitivity of the Japanese version of the University of California Los Angeles scleroderma clinical trial consortium gastrointestinal tract instrument: Application to efficacy assessment of intravenous immunoglobulin administration.
Matsuda KM; Sugimoto E; Ako Y; Kitamura M; Miyahara M; Kotani H; Norimatsu Y; Hisamoto T; Kuzumi A; Fukasawa T; Sato S; Yoshizaki A
J Dermatol; 2024 Jun; 51(6):741-751. PubMed ID: 38558171
[TBL] [Abstract][Full Text] [Related]
8. Validation of Serbian version of UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in 104 patients with systemic sclerosis.
Zekovic A; Damjanov N
Rheumatol Int; 2017 May; 37(5):735-741. PubMed ID: 28271157
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of gastroesophageal reflux disease symptoms and effects of esomeprazole on the quality of life related to reflux and dyspepsia in patients on maintenance hemodialysis.
Namikoshi T; Harada K; Hatta H; Tokura T; Oshiro Y; Nishizaki T; Obata T; Mori M; Fueki T; Fujimoto S; Haruna Y; Kuwabara A; Yorimitsu D; Ihoriya C; Kadoya H; Itano S; Fujimoto Y; Komai N; Sasaki T; Kashihara N
Clin Exp Nephrol; 2016 Feb; 20(1):134-42. PubMed ID: 26026991
[TBL] [Abstract][Full Text] [Related]
10. Gastroesophageal Reflux Disease-Related Disorders of Systemic Sclerosis Based on the Analysis of 66 Patients.
Matsuda R; Yamamichi N; Shimamoto T; Sumida H; Takahashi Y; Minatsuki C; Kodashima S; Ono S; Niimi K; Tsuji Y; Sakaguchi Y; Saito I; Kataoka Y; Asada-Hirayama I; Kakimoto H; Yakabi S; Takeuchi C; Matsumoto Y; Tamaki Z; Fujishiro M; Asano Y; Sato S; Koike K
Digestion; 2018; 98(4):201-208. PubMed ID: 30045036
[TBL] [Abstract][Full Text] [Related]
11. Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 instrument as a clinical decision aid in the routine clinical care of patients with systemic sclerosis.
Zampatti N; Garaiman A; Jordan S; Dobrota R; Becker MO; Maurer B; Distler O; Mihai C
Arthritis Res Ther; 2021 Apr; 23(1):125. PubMed ID: 33888149
[TBL] [Abstract][Full Text] [Related]
12. The impact of gastroesophageal reflux disease symptoms in scleroderma: effects on sleep quality.
Horsley-Silva JL; Umar SB; Vela MF; Griffing WL; Parish JM; DiBaise JK; Crowell MD
Dis Esophagus; 2019 May; 32(5):. PubMed ID: 30715227
[TBL] [Abstract][Full Text] [Related]
13. Translation, cross-cultural adaptation, and validation of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument (SCTC GIT) 2.0 into Dutch.
Meijs J; Pors D; Vliet Vlieland TP; Huizinga TW; Schouffoer AA
Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-41-8. PubMed ID: 24984228
[TBL] [Abstract][Full Text] [Related]
14. Reliability and validity of the Korean version of the University of California-Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract instrument in patients with systemic sclerosis.
Lee TH; Lee JS; Park S; Lee KA; Kim HS
Korean J Intern Med; 2021 Nov; 36(6):1504-1514. PubMed ID: 33561335
[TBL] [Abstract][Full Text] [Related]
15. Reliability and validity of the Italian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in patients with systemic sclerosis.
Gualtierotti R; Ingegnoli F; Two R; Meroni PL; Khanna D; Adorni G; Becciolini A; Ciavarella T; Marfia G; Murgo A; Scalone L; Ughi N; Zeni S;
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S55-60. PubMed ID: 26339890
[TBL] [Abstract][Full Text] [Related]
16. Progression of gastrointestinal symptoms over time in patients with systemic sclerosis.
Bering J; Griffing WL; Crowell M; Umar SB
Rheumatol Int; 2021 Jul; 41(7):1281-1287. PubMed ID: 33630144
[TBL] [Abstract][Full Text] [Related]
17. Relationship Between Gastrointestinal Transit, Medsger Gastrointestinal Severity, and University of California-Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0 Symptoms in Patients With Systemic Sclerosis.
McMahan ZH; Tucker AE; Perin J; Volkmann ER; Kulkarni S; Ziessman HA; Pasricha PJ; Wigley FM
Arthritis Care Res (Hoboken); 2022 Mar; 74(3):442-450. PubMed ID: 33064934
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and correlates of sleep disturbance in systemic sclerosis--results from the UCLA scleroderma quality of life study.
Frech T; Hays RD; Maranian P; Clements PJ; Furst DE; Khanna D
Rheumatology (Oxford); 2011 Jul; 50(7):1280-7. PubMed ID: 21324979
[TBL] [Abstract][Full Text] [Related]
19. Associations between a scleroderma-specific gastrointestinal instrument and objective tests of upper gastrointestinal involvements in systemic sclerosis.
Bae S; Allanore Y; Furst DE; Bodukam V; Coustet B; Morgaceva O; Maranian P; Khanna D
Clin Exp Rheumatol; 2013; 31(2 Suppl 76):57-63. PubMed ID: 23910611
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of a simple and multifaceted instrument, GERD-TEST, for the clinical evaluation of gastroesophageal reflux and dyspeptic symptoms.
Nakada K; Matsuhashi N; Iwakiri K; Oshio A; Joh T; Higuchi K; Haruma K
World J Gastroenterol; 2017 Jul; 23(28):5216-5228. PubMed ID: 28811716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
